Molecular and Cellular Pathobiology

Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2

Shasha Tao1, Shue Wang2, Seyed Javad Moghaddam3, Aikseng Ooi1, Eli Chapman1, Pak K. Wong2, and Donna D. Zhang1

Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona.2Department of Aerospace and Mechanical Engineering, The University of Arizona, Tucson, Arizona.3Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

Oncogenic KRAS mutations found in 20% to 30% of all non–small cell lung cancers (NSCLC) are associated with chemoresistance and poor prognosis. Here we demonstrate that activation of the cell protective stress response gene NRF2 by KRAS is responsible for its ability to promote drug resistance. RNAi-mediated silencing of NRF2 was sufficient to reverse resistance to cisplatin elicited by ectopic expression of oncogenic KRAS in NSCLC cells. Mechanistically, KRAS increased NRF2 gene transcription through a TPA response element (TRE) located in a regulatory region in exon 1 of NRF2. In a mouse model of mutant KrasG12D-induced lung cancer, we found that suppressing the NRF2 pathway with the chemical inhibitor brusatol enhanced the antitumor efficacy of cisplatin. Cotreatment reduced tumor burden and improved survival. Our findings illuminate the mechanistic details of KRAS-mediated drug resistance and provide a preclinical rationale to improve the management of lung tumors harboring KRAS mutations with NRF2 pathway inhibitors. Cancer Res; 74(24); 7430–41. ©2014 AACR.

Introduction

The RAS genes encode a family of membrane-associated 21-kDa GTP-binding proteins, including HRAS, KRAS, and NRAS that control cell growth, differentiation, and apoptosis. By switching from the GTP-bound active form to the GDP-bound inactive form, RAS proteins function as a molecular switch to turn on or off their downstream effectors (1, 2). Although each of the 3 RAS genes can be mutated in human cancers, KRAS mutations are the most common. Oncogenic KRAS mutations occur in approximately 30% of all cancer types and in 20% to 30% of non–small cell lung cancers (NSCLC; ref. 3). These oncogenic mutations frequently occur as point mutations in codons 12, 13, or 61, each resulting in a protein with impaired GTPase activity and, therefore, constitutive activation of RAS signaling (3, 4). A large body of literature has reported that cancers with oncogenic KRAS mutations are resistant to anticancer drug treatments and thus patients with these malignancies have poor prognoses (5–9). Mechanistically, chemoresistance may be explained by (i) mutation or overexpression of a therapeutically targeted protein, (ii) inactivation of the drug, (iii) reduced drug uptake, (iv) enhanced efflux of the drug, or (v) the recovery of drug-induced DNA lesions by DNA repair enzymes (10).

NRF2 is a transcription factor that regulates the antioxidant response by inducing the expression of genes bearing an antioxidant response element (ARE) in their regulatory regions. Activation of the NRF2 pathway promotes cell survival during oxidative stress or xenobiotic insult (11–14). Importantly, many of the NRF2 target genes, including drug-metabolizing enzymes, antioxidant enzymes, and drug transporters, play a crucial role in determining drug resistance (14). Examples of NRF2 target genes that may confer enhanced drug processing include glutamate-cysteine ligase (GCLC/GCLM), thioredoxin reductase 1 (TXNRD1), aldo-keto reductase (AKR), glutathione S-transferase (GST), multidrug resistance–associated protein 2 (MRP2), NAD(P)H quinone oxidoreductase 1 (NQO1), and heme oxygenase 1 (HMOX1).

It has been demonstrated that NRF2 has a dual role in cancer. First, NRF2 is involved in chemoprevention. Oxidative stress is implicated in the initiation and progression of cancer. Under oxidative stress, NRF2 induces the transcription of hundreds of cellular protective genes to combat potentially carcinogenic reactive intermediates. As evidence for this protective role, many chemopreventive compounds have been identified as NRF2 activators (11–15), and Nrf2-null mice are highly susceptible to chemical carcinogens and are no longer protected by chemopreventive compounds (16, 17). Second, recent findings point to a "dark side" of NRF2 that promotes cancer (18). Many studies have shown that cancers can harbor somatic mutations in NRF2, KEAP1, or CUL3 that disrupt the KEAP1-mediated
negative regulation of NRF2, resulting in a constitutive high level of NRF2 (19–22), which correlates with chemoresistance in cancer cells (13, 18, 23–26). Discovery of the cancer-promoting activity of NRF2 has prompted us to identify compounds that inhibit the NRF2 pathway (27). We previously identified a potent NRF2 pathway inhibitor, brusatol, which inhibits the NRF2-mediated protective response at subnanomolar concentrations. Brusatol treatment also enhances the efficacy of chemotherapeutics in an NRF2-dependent manner in both cell culture and murine A549 xenograft models.

Previous studies have demonstrated that NRF2 is primarily regulated at the protein level by the ubiquitin–proteasome system (UPS). Under physiologic conditions, NRF2 levels are low in all organs due to tight regulation by KEAP1, a substrate adaptor protein for a Cullin3-based E3 ubiquitin ligase (28–31). Under these basal conditions, this E3 ligase constantly targets NRF2 for ubiquitylation and subsequent proteasomal degradation. Upon activation of the pathway by oxidative or electrophilic stress, the enzymatic activity of the E3 ligase is inhibited, resulting in stabilization of NRF2 and transcriptional activation of its target genes (13). Recently, another E3 ubiquitin ligase, β-TrCP-Skp1-Cull-Rbx1, was also found to ubiquitylate Nrf2 (32–34). In addition, we have identified another E3 ubiquitin ligase, HRD1, that compromises the NRF2-mediated cytoprotective mechanism during the pathogenesis of liver cirrhosis (35). All these studies indicate that NRF2 is controlled at the protein level through protein stability modulation. Furthermore, many NRF2 modulators, including small molecules and endogenous proteins, upregulate NRF2 signaling by increasing the stability and thus the protein level of NRF2 without affecting its mRNA level (13). Interestingly, a recent study reported in a murine model a 1.6-fold increase in the mRNA level of Nrf2 in response to activation of oncogenic alleles of KrasG12D, B-RafV617F, and c-MycCrt12 (36). However, the molecular mechanisms underlying increased Nrf2 transcription were not reported. In the current study, we provide strong evidence that oncogenic KrasG12D transcriptionally upregulates the mRNA levels of NRF2 through a TRE enhancer located in the proximal promoter of NRF2. More importantly, we show that inhibition of the NRF2 pathway by brusatol was able to overcome KRAS-mediated chemoresistance and thus enhanced the efficacy of cisplatin.

**Materials and Methods**

**Cell lines and cell culture**

Human bronchial epithelial (HBE) cells were obtained from Dr. Dieter Gruenert, whose laboratory generated and characterized them (37); the rest were purchased from the ATCC, Dr. Dieter Gruenert, whose laboratory generated and characterized them (37); the rest were purchased from the ATCC.

Construction of recombinant DNA molecules

The KRASWT, KRASG12D, and KRASDN expression vectors were constructed by cloning a PCR-generated fragment into pcDNA 3.1 (Invitrogen). Deletion fragments of the NRF2 promoter sequence were amplified by PCR from gDNA extracted from HBE cells and cloned into pGL4.22 (Promega). The fragment named "TRE," located between bases +267 and +273 in NRF2's promoter sequence, including a sequence similar to AP-1 recognition site ("TGCGTCA"), was purchased (Sigma) and inserted into pGL4.22 after end-repairing and annealing the 2 oligos together. All the sequences were confirmed by direct nucleotide sequencing.

**Transfection of siRNA and cDNA**

Transfection of cDNA was performed using Lipofectamine 2000 (Invitrogen). HiPerfect (Qiagen) was used for transfection of siRNA. NRF2 siRNA#3 (S100657937), NRF2 siRNA#5 (S10387289), and control siRNA (1027281) were purchased from Qiagen. Both siRNA#3 and siRNA#5 were able to specifically reduce the Nrf2 protein level without off-target effects (Supplementary Fig. S1). siRNA#5 was used for all the data presented in this article.

**Luciferase reporter gene assay**

HEK293 cells were transfected with several deletion fragments of NRF2 promoter–luciferase constructs along with thymidine kinase (TK)-Renilla luciferase (internal control). Luciferase activities were measured with the Dual Luciferase Reporter Assay System (Promega). Experiments were performed in triplicates.

**Cell viability**

Cisplatin-induced toxicity was measured by functional impairment of mitochondria using MTT (Sigma) as previously described (38). Approximately 1.5 × 10⁴ NCI-H292 cells per well were seeded in a 96-well plate and transfected with either siRNA or vectors expressing KRASDN, KRASG12D, or KRASWT before treatment with the indicated concentrations of cisplatin for 48 hours. Experiments were done in triplicates.

**mRNA extraction and real-time quantitative reverse transcription-PCR**

Total mRNA was extracted using TRIzol (Invitrogen) according to the manufacturer’s instructions. cDNA was synthesized using equal amounts of mRNA and the Transcriptor
first-strand cDNA synthesis kit (Promega). The detailed Taq-
Man probe and primer sequences can be seen in the Supple-
mentary Materials and Methods. Real-time PCR (RT-PCR) was
performed as previously described (38). Reactions for each
sample were done in duplicate, and the experiment was
repeated three times. Results are expressed as relative mRNA
levels normalized to GAPDH.

Quantification of cDNA amounts for Nrf2, Keap1, Nqo1,
Akr1b10, Akr1c1, Gclm, Hmox1, and β-actin from tissues was
performed with KAPA SYBR qPCR Kit (Kapa Biosys-
tems). All primer sets were designed with Primer 3 free online
software and synthesized by Sigma. Sequences can be found in
the Supplementary Materials and Methods. The RT-PCR was
performed as previously described (38). All reporter gene and
RT-PCR analyses were done in duplicates and repeated in three
independent experiments.

Immunoblot analysis

Protein expression from cell lines and lung tissues was
assessed by SDS-PAGE and immunoblotting as described
previously (38). For details on sample collection, see Supple-
mentary Materials and Methods.

Apoptotic cell death (TUNEL)

Briefly, lung epithelium tissue sections were pretreated with
proteinase K (15 μg/ml) in 10 mmol/L Tris-HCl (pH 7.8) at
37°C for 30 minutes, and an in situ cell death detection kit
(Roche) was used for detecting apoptotic cell death according
to the manufacturer's instructions. Tissue sections were then
coated with Hoechst and analyzed with a fluorescence
microscope (Zeiss Observer.Z1 microscope with the Slidebook
software).

Materials and antibodies

Cisplatin and U0126 were purchased from Sigma-Aldrich.
Horseradish peroxidase-conjugated secondary antibodies as
well as primary antibodies against NRF2, KEAP1, p-ERK,
ERK, KRAS, GCLM, HMOX1, AKR1B10, AKR1C1, NQO1, KI67,
Lamin-A, and GAPDH were purchased from Santa Cruz Bio-
technology. Primary antibody against γ-H2A was purchased
from Bethyl Laboratories, Inc. Primary antibody against 8-
dihydro-2′-deoxyguanosine (8-oxo-dG) was purchased from
Trevigen.

Experimental animals

Six-week-old C57Bl6 LSL-Kras<sup>G12D</sup> mice were purchased
from Jackson Laboratory. The C58S<sup>Cre</sup> mice were reported
previously (39–41). C58S<sup>Cre</sup>/LSL-Kras<sup>G12D</sup> mice were gener-
ated by cross breeding a mouse harboring the LSL-Kras<sup>G12D</sup>
allele with a mouse containing Cre recombinase inserted into the
Clara cell secretory protein (CCSP) locus. All mice were housed
in specific, pathogen-free conditions and handled in accor-
dance with the Institutional Animal Care policies. Mice were
intrapertioneally injected with cisplatin and brusatol for both
short- and long-term treatments. Tissues were harvested at the
indicated time points and the mice were monitored daily for
evidence of disease or death.

Tissue collection, hematoxylin and eosin staining, and
immunohistochemistry

Lung tissues were isolated at the indicated time points
(Fig. 4A). After images were collected, surface tumors were
weighted and counted using a dissecting microscope. One
half of the lung was directly frozen in liquid nitrogen and
stored at -80°C for total RNA extraction and for immuno-
blot analysis, and the other half was fixed in 10% buffered
formalin and embedded in paraffin. Five-micrometer sec-
tions were cut and stained with hematoxylin and eosin
(H&E). Immunohistochemical (IHC) analysis was performed
as previously described (38).

Oxidative DNA damage

A monoclonal antibody against 8-Oxop7, 8-oxo-dG (Trevi-
gen) was used for the detection of oxidative DNA damage. The
staining was performed as previously described (42).

Detection of mRNA level in the fresh tumor lung tissue
slides by double-stranded locked nucleic acid probes

Four locked nucleic acid (LNA) probes were designed as
previously described (43) to detect the relative gene expres-
sion levels of Nrf2, Hmox1, Nqo1, and Akr1c1 in both tumor
and normal lung tissues. A β-actin probe and a random
probe were designed as the positive and negative controls.
The gold nanorod (GNR)–LNA complex solution including
0.1 μmol/L LNA probe and 2.5 × 10<sup>11</sup> GNR/mL was added to the
lung slices in 24-well plates. After incubation for 8 hours
at 37°C, the slices were washed with PBS three times and
imaged with an inverted fluorescence microscope with an
HQ2 CCD camera. Data collection and imaging analysis were
performed in ImageJ.

Statistical analysis

Results are presented as the mean ± SEM of at least three
independent experiments performed in duplicates or triplicates.
Statistical tests were performed using SPSS 10.0. Unpaired
Student t tests were used to compare the means of two groups.
One-way ANOVA was applied to compare the means of three
or more groups. P < 0.05 was deemed significant.

Results

Expression of oncogenic KRAS enhances cisplatin
resistance by upregulating the NRF2-mediated
protective response

To show that chemoresistance observed in tumors ex-
pressing oncogenic KRAS is associated with activation of
NRF2 signaling, we first compared the NRF2 protein level
with that of the phosphorylated form of the ERK (p-ERK; a
readout of KRAS activation) in several lung cell lines (Sup-
plementary Fig. S2). Their response to cisplatin-mediated
toxicity was measured and LD<sub>50</sub> values are listed (Supple-
mentary Table S1). The coding regions of NRF2 and KRAS
were sequenced and the status of each gene is listed; the
mutation information of KRAS

Published OnlineFirst October 22, 2014; DOI: 10.1158/0008-5472.CAN-14-1439

Downloaded from cancerres.aacrjournals.org on May 4, 2017. © 2014 American Association for Cancer Research.
in Supplementary Table S1, we selected a human lung epithelial carcinoma cell line (NCI-H292) and an immortalized but not transformed HBE cell line for further studies. Both NCI-H292 and HBE have no mutations in KEAP1, NRF2, TP53, or KRAS and have basal levels of p-ERK (Supplementary Fig. S2). Overexpression of KRASG12D or, to a lesser extent, wild-type KRAS (KRASWT) enhanced cell viability in response to cisplatin treatment, whereas overexpression of a dominant-negative KRAS mutant (KRASDN) reduced cell viability in both cell lines (Fig. 1A and C, top). The effect of KRAS overexpression in cisplatin resistance was shown to be NRF2-dependent, as it was lost when NRF2 expression was silenced by siRNA (Fig. 1A and C, bottom).

We noticed that the LD50 for HBE cells shifted from 9.6 μmol/L (Supplementary Table S1) to 3 μmol/L (Fig. 1C) after transfection with control siRNA, whereas transfection of control siRNA had no effect on the LD50 of NCI-H292 (LD50 = 2.3, Supplementary Table S1 and Fig. 1A). This might be due to the fact that HBE, a primary cell line, is more sensitive to the transfection reagent compared with the cancer cell line NCI-H292.

As expected, overexpression of KRASG12D and KRASWT activated the ERK pathway as indicated by enhanced p-ERK, whereas total ERK remained the same (Fig. 1B and D).

Figure 1. Expression of oncogenic KRAS enhances chemoresistance by upregulating the NRF2-mediated protective response. A and C, overexpression of the oncogenic form of KRAS protected NCI-H292 and HBE cells against cisplatin-mediated cell toxicity in an NRF2-dependent manner. NCI-H292 and HBE cells were transfected with control siRNA (top) or NRF2 siRNA (bottom) for 24 hours, followed by transfection of an empty vector or the indicated KRAS mutant. At 24 hours posttransfection of cDNA, the indicated dose of cisplatin was added and cell viability was measured 48 hours after cisplatin treatment. Data are expressed as mean ± SEM (*, P < 0.05, KRAS vs. control group). B and D, a positive relationship between activation of the KRAS pathway and the NRF2 pathway. An aliquot of cells, transfected and treated as described in A and C, was harvested, and cell lysates were subjected to immunoblot analysis.
Interestingly, overexpression of KrasG12D and KrasWT also increased the levels of NRF2 and its target genes, GCLM and HMOX1 (Fig. 1B and D), indicating activation of the NRF2 pathway. Conversely, ectopic expression of KrasDN slightly reduced p-ERK, NRF2, GCLM, and HMOX1 levels (Fig. 1B and D). Immunoblot analyses confirmed NRF2 silencing by NRF2-siRNA, as expression of NRF2, GCLM, and HMOX1 was dramatically reduced (Fig. 1B and D). Taken together, these results demonstrate that the KRAS–ERK pathway positively regulates the NRF2 pathway, indicating that KRAS-mediated cisplatin resistance may be due to activation of the NRF2 pathway.

KrasG12D-induced lung tumor tissues have higher levels of Nrfl2 of Nrfl2 and its target genes

To confirm that oncogenic KRAS upregulates the NRF2 pathway, a murine lung cancer model (LSL-KrasG12D−/−) was used. Cre-virus intratracheal infection of LSL KrasG12D−/− mice for 8 weeks resulted in multiple lung adenomas. Tumor tissues from each mouse were pooled, and Kras activation, and the expression of Nrfl2 and its target genes in tumor tissues were compared with those in normal lung tissues. As expected, Kras was activated in tumors, where marked elevation of p-ERK was only observed in tumor but not normal tissues. Comparatively, Erk was expressed equally in tumor versus normal tissues (Fig. 2A). Remarkably, the expression of Nrfl2 and its target genes Akr1b10, Akr1c1, Gclm, and Nqo1 was dramatically increased in tumor tissues as compared with the corresponding normal tissues. Notably, the activation of the Nrfl2 pathway by oncogenic Kras was more substantial in mice than in cultured cells (compare Fig. 2A with 1B). IHC analyses demonstrated that Nrfl2 and Nqo1 were highly expressed in tumors compared with adjacent normal tissues or normal control lungs (Fig. 2B and Supplementary Fig. S4). In addition, the mRNA levels of Nrfl2, Hmox1, Nqo1, Gclm, Akr1b10, and Akr1c1 were significantly higher in tumor than in normal tissues, whereas Keap1 mRNA was expressed at a similar level in both tissues (Fig. 2C). To further confirm the real-time RT-PCR data and to visualize the mRNA expression in tumor versus normal tissues, we used our newly developed method, a GNR–LNA complex, for single-cell gene expression detection in living cells and tissues (44). The fluorescence intensities of Nrfl2, Nqo1, Hmox1, and Akr1c1 were higher in tumor tissues than in the adjacent normal tissues, whereas the signal for a random probe or β-actin was similar between both (Fig. 2D). Taken together, these results demonstrate that KrasG12D upregulates the Nrfl2 pathway by increasing the level of Nrfl2 mRNA.

KRAS transcriptionally activates NRF2 through the TRE

To understand how activation of the KRAS–ERK pathway upregulates the Nrfl2 mRNA levels, we made a series of reporter constructs with truncated Nrfl2 regulatory regions cloned upstream of a luciferase gene. KrasG12D and KrasWT, but not KrasDN, significantly enhanced the luciferase activity in all constructs except for construct F5-R1, indicating that potential enhancer sequence(s) are flanked by primers F4 and F5 (+227 to +403; Fig. 3A, left). Similarly, another set of reporter gene analyses localized enhancer sequence(s) to the B3-B4 region (-234 to +343; Supplementary Fig. S3). A computational search for enhancers identified a TRE sequence between +267 and +273. Therefore, the TRE sequence TGGCTAC flanked by 15 nucleotides on both sides was inserted into the luciferase reporter gene vector (TRE, Fig. 3A, right). TRE was upregulated by KrasG12D and KrasWT, not KrasDN (Fig. 3A, right). Next, the TRE core sequence TGGCTAC was mutated to AACCTAC in both F3-R1 and F4-R1 constructs (F3-R1 Mu and F4-R1 Mu). KrasG12D and KrasWT were no longer able to enhance luciferase activities of F3-R1 Mu and F4-R1 Mu (Fig. 3A, right). These results demonstrate that KRAS upregulates Nrfl2 mRNA through the TRE. To confirm that this KRAS-mediated transcriptional upregulation of Nrfl2 is through MEK–ERK signaling, an MEK inhibitor U0126 was used. U0126 suppressed p-ERK and inhibited both basal and KRAS-induced Nrfl2, GCLM, and HMOX1 protein (Fig. 3B, left) and mRNA levels (Fig. 3B, right).

Brusatol cotreatment reduces tumor burden and enhances survival

To test whether brusatol cotreatment is able to overcome KRAS tumor resistance to cisplatin, an LSL-KrasG12D−/− murine lung cancer model was chosen. To generate consistent tumor numbers in the lung, Ccsfcre/cre mice were crossed with LSL-KrasG12D−/− to generate Ccsfcre/cre/LSL-KrasG12D−/− mice. These mice developed multiple lesions such as atypical adenomatous hyperplasia, adenoma, and adenocarcinoma by 16 weeks of age (39–41). Two sets of experiments were carried out: a short-term treatment experiment, which consisted of one treatment regimen (Fig. 4A, left) to test whether the combination of brusatol with cisplatin could sensitize cancer cells to overcome intrinsic resistance; and a long-term treatment experiment, which consisted of two treatment regimens (Fig. 4A, right) to test the possible role of Nrfl2 in long-term cisplatin-induced resistance (acquired resistance), as was previously observed in this model (10). Mice in the untreated control group had a median survival of 9 months and died by 10 months (Fig. 4B). In the cisplatin single-agent–treated group, all mice died at 13 months in the short-term studies (right); brusatol single-agent treatment showed similar effects. The survival of the cotreatment group significantly increased in both short- and long-term experiments. Cotreatment increased the median survival from 11.5 months (single agent) to 15 months in the short-term experiment and from 12.5 and 13.5 (single agent) to 15.5 months in the long-term experiment. At the end of our experiments, 20% of the short-term and 40% of the long-term mice in the cotreatment group survived beyond 20 months. Mice were harvested 40 days postinjection in the short-term group or 62 days postinjection in the long-term group for evaluation of the lungs. Morphologic differences were readily apparent in the lung from the treated versus untreated groups. The lungs in the cotreated groups showed the most normal tissue texture (Fig. 4C), had the lowest wet
lung weights (Fig. 4D), the lowest number of grossly visible surface tumors (Fig. 4E), and the smallest size of tumors (Fig. 4F and G) in both the short- and the long-term studies. In the short-term studies, only the untreated group had one tumor with a diameter > 5 mm, whereas in the long-term study, there were no tumors > 5 mm in the cotreatment group, but five mice in the control, two mice in the cisplatin group, and three mice in the brusatol group had them (Fig. 4G). Next, we classified the histopathology of lesions observed in different groups (AAH and adenomas vs. adenocarcinomas). The percentage of mice with adenocarcinomas in the cotreatment group was relatively low (Supplementary Table S2).
The number of lesions was lowest in the cotreatment group (Supplementary Fig. S7).

**Brusatol cotreatment enhances the efficacy of cisplatin through Nrf2 inhibition in KrasG12D tumors**

As expected, brusatol treatment markedly suppressed the protein levels of Nrf2, Akr1b10, Akr1c1, Nqo1, and Gclm, without affecting proteins in the Kras pathway, as indicated by p-Erk (Fig. 5A). Cisplatin treatment resulted in a slight increase in p-Erk (Fig. 5A) consistent with previous findings (45). Brusatol also decreased the mRNA levels of Nqo1, Akr1b10, Akr1c1, Hmox1, and Gclm without affecting Nrf2 and Keap1 mRNA levels (Fig. 5B). Brusatol and cisplatin cotreatment significantly reduced tumor volume, as measured by Ki67 expression and this was further reduced by cisplatin and brusatol cotreatment. γ-H2AX staining showed that the greatest DNA damage occurred in the tumors of mice cotreated with brusatol and cisplatin. Similarly, oxidative damage was the highest in the tumors of cotreated mice as measured by IHC staining of 8-oxo-dG. Measurement of apoptotic cell death using terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) analysis indicated that the largest degree of cell death occurred in the cotreatment group. Collectively, these results demonstrate that brusatol-mediated inhibition of the Nrf2 pathway enhanced the efficacy of cisplatin treatment through reduced cell proliferation, enhanced DNA damage, and increased apoptotic cell death.

**Discussion**

In the present study, we found that oncogenic mutation of KRAS or KRAS overexpression enhanced resistance of cells to...
cisplatin in an NRF2-dependent manner (Fig. 1). We then investigated the molecular mechanism of KRAS-mediated chemoresistance and found a novel mode of NRF2 activation by KRAS. Distinct from the previously defined UPS-mediated NRF2 regulatory mechanisms, we demonstrate that KRAS is able to transcriptionally activate NRF2 through the KRAS–ERK pathway. A TRE enhancer sequence located between +267 and +273 of the NRF2 exon 1 was identified, and its upregulation by oncogenic KRAS was confirmed (Figs. 2 and 3). Using our newly established GNR–LNA technique for detecting single-cell mRNA expression in living tissues, we observed a marked increase in the mRNA level of Nrf2 in lung tumor tissues compared with the adjacent normal tissues (Fig. 2D, Nrf2), further confirming that activation of the Nrf2 pathway by KRAS is through enhanced Nrf2 mRNA expression. Notably, Kras-mediated upregulation of Nrf2 and its target genes was more robust in the in vivo murine system when tumor tissues were compared with normal tissues than in the in vitro cell–based system when different forms of KRAS were ectopically expressed and their effects compared (Figs. 1–3). In addition,
we presented a potential means of mitigating KRAS-induced drug resistance through cotreatment with chemotherapeutics (cisplatin) and an NRF2 inhibitor (brusatol; Figs. 4 and 5).

Cancer is the second leading cause of death in developed countries; it is responsible for about 600,000 deaths in the United States annually, and the incidence and mortality have been steadily increasing. Lung cancer is one of the most commonly diagnosed cancers, comprising 15% to 30% of total cancer cases. In NSCLC, the prevalence of oncogenic KRAS mutations is approximately 20% to 30% (3). Lung cancer is the leading cause of cancer-related death worldwide, with a 5-year survival rate of less than 15%. The death rate for lung cancer has increased dramatically over the past several decades, even though death rates for other cancer types either remain the same or have decreased. Currently, radiation and platinum-based drugs are the standard treatments (46, 47). However, the toxicity profiles and high rate of relapse with platinum compounds limit both their usefulness and effectiveness.

Figure 5. Brusatol cotreatment enhances the efficacy of cisplatin through NRF2 inhibition in KrasG12D tumors. Results from short-term treatment (left) and long-term treatment (right) are shown. A, brusatol treatment significantly inhibited the NRF2 signaling pathway. Lung tissue lysates from each group were subjected to immunoblot analysis with the indicated antibodies. Each lane contains a lung tissue sample from individual mice. B, brusatol inhibited the mRNA level of Nr2 target genes. An aliquot of the same lung tissue sample was used for quantitative real-time RT-PCR to measure the relative mRNA level of Nr2, Keap1, Nqo1, Akrt10, Akrt1c1, Hxom1, and Gclm. Data are expressed as mean ± SEM (n = 3; *, P < 0.05; Ctrl vs. treated group). C, lowest tumor volume was observed in the cotreatment group (Bru + Cis). A representative H&E staining of lung tissues from each group (n = 10) is shown. The ratio of tumor area/total lung area was quantified (*, P < 0.05; control vs. treatment groups; #, P < 0.05; Cis vs. Bru + Cis groups). D, IHC staining with NRF2, NQO1, AKR1C1, Ki67, γ-H2AX, and 8-oxo-dG antibodies of lung tissue sections from CCSPCre/Cre/LSL-KrasG12D/ mice treated with PBS, Cis, Bru, or Bru + Cis (scale bar, 100 μm). Lung sections were stained with TUNEL as a measurement of cell death and Hoechst was included to label the nucleus. A representative image from each group (n = 3) is shown.
Therefore, there is an urgent need to develop new adjuvants to enhance the efficacy of platinum-based treatments and circumvent chemoresistance.

Recent studies have clearly demonstrated the association between high NRF2 activity and chemoresistance in cancers. For example, somatic gain-of-function mutations of NRF2 or somatic loss-of-function mutations of either KEAP1 or CUL3 (CUL3) are frequently found in lung cancer. KEAP1 mutations were identified at a frequency of 50% (6 of 12) or 19% (10 of 54) in NSCLC cancer cell lines or tumor samples, respectively. In addition, LOH at 19p13.2, where KEAP1 is located, was observed at a frequency of 61% or 41% in NSCLC cell lines (72 samples in total) or in tumor tissues (39 samples in total; ref. 20). In a similar study, somatic mutations were found in 5 of 65 (8%) patients who had adenocarcinoma, squamous cell carcinoma, or large cell carcinoma (21). Another study that looked at the NRF2 and KEAP1 protein levels in 304 NSCLC tissues reported that 26% of the studied cohort had high nuclear NRF2 levels, whereas 56% had low KEAP1 levels (22). Similarly, mutations in NRF2 that disrupt KEAP1-mediated repression can also result in high NRF2 activity. For example, NRF2 mutations were found in 10 of 125 (8.0%) lung cancer cases (48). In this study, we extended the previous findings that link high NRF2 expression in NSCLC with cisplatin resistance in KRAS-positive lung cancers. As demonstrated, KRAS upregulated NRF2 mRNA, which activated NRF2-mediated protective mechanisms, conferring cisplatin resistance.

Inhibiting the NRF2-mediated protective mechanism to enhance the efficacy of cancer therapeutics represents an innovative approach to cancer treatment. As reported previously, we isolated brusatol from Brueca javanica (L.) Merr., a plant native to South-east Asia and Australia, which inhibits NRF2 (27). We previously demonstrated that brusatol was able to sensitize a broad spectrum of cancer cell lines and A549-derived xenografts to many chemotherapeutic drugs in an NRF2-dependent manner (27). Here, we further explored the idea that brusatol can be developed as an adjuvant to enhance the efficacy of chemotherapeutic drugs using a preclinical lung adenocarcinoma model in CCSPCre/KrasG12D mice where tumors were induced by oncogenic Kras. Compared with cisplatin or brusatol treatment alone, cotreatment of brusatol and cisplatin significantly reduced the number and the size of the tumors and improved survival (Fig. 4). In addition to intrinsic resistance, we also demonstrated that brusatol is more effective in long-term cisplatin-induced resistance (acquired resistance; Fig. 4). Brusatol cotreatment inhibited the Nrf2 protective mechanism and led to decreased cell proliferation, enhanced oxidative DNA damage, and apoptotic cell death (Fig. 5). In the current study, we did not observe any adverse effects with the regimens used in the C57BL6 strain. However, higher doses of brusatol were observed to cause a decrease in the body weight of nude mice. Therefore, local delivery of brusatol, such as aerosol administration into the lung, may be superior over the systemic intraperitoneal injection, which warrants further investigation. In summary, our results demonstrate that oncogenic activation of KRAS and KRAS amplification can activate the NRF2-mediated protective mechanism, resulting in chemoresistance. Therefore, brusatol, an NRF2 inhibitor, can be used as an adjuvant to sensitize tumors with KRAS activation, in addition to those tumors resulting from KEAP1 or NRF2 mutations. This work provides a framework for the development of NRF2 inhibitors into therapeutic drugs to combat chemoresistance. Future studies investigating the contribution of KRAS-mediated transcriptional upregulation of NRF2 in chemoresistance using human lung tumor tissues will define the penetrance of this mechanism of resistance.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: S. Tao, A. Ooi, E. Chapman, P.K. Wong, D.D. Zhang
Development of methodology: S. Tao, S. Wang, S.J. Moghaddam, P.K. Wong, D.D. Zhang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Tao, S. Wang, S.J. Moghaddam, D.D. Zhang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Tao, S. Wang, E. Chapman, P.K. Wong, D.D. Zhang
Writing, review, and/or revision of the manuscript: S. Tao, S. Wang, S.J. Moghaddam, A. Ooi, E. Chapman, P.K. Wong, D.D. Zhang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Tao, S. Wang, P.K. Wong
Study supervision: P.K. Wong, D.D. Zhang

Acknowledgments
The authors give special thanks to Montserrat Rojo de la Vega for proofreading this article.

Grant Support
This research article was funded by CA154377 and ES015010 (D.D. Zhang), DP2OD007161 (P.K. Wong), and ES006694 (a center grant).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 19, 2014; revised September 24, 2014; accepted October 9, 2014; published OnlineFirst October 22, 2014.

References

7. Wei F, Li Y, Bellai AC, Olson JJ, Sun SY, Lu G, et al. K-Ras mutation-


13. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 sig-


15. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemothera-
pic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235–43.


21. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant tran-


23. Raja P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cua-
Drado A. SCF(β-TrCP) promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription fac-
tor in a Keap1-independent manner. Mol Cell Biol 2011;31:1121–33.


25. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 2013;32:3765–81.


27. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription pro-


33. Zhang Y, Tao S, Lian F, Chau BT, Chen J, Sun G, et al. Sulfophare prevents pulmonary damage in response to inhaled arsenic by acti-


Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2

Shasha Tao, Shue Wang, Seyed Javad Moghaddam, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-1439

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/10/22/0008-5472.CAN-14-1439.DC1

Cited articles
This article cites 48 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/24/7430.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/74/24/7430.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.